Search Results

RaySearch Laboratories: Interim report January 1 - March 31, 2024.

RaySearch Laboratories AB announces the launch of RayStation®* 2024B, the latest version of the company’s innovative treatment planning system.

RaySearch Laboratories AB and C-RAD are pleased to announce a collaboration agreement, aiming at jointly developing innovative solutions and products to enhance the quality of radiation therapy.

RaySearch Laboratories AB will present the latest software innovations at IBA’s International Symposium on Proton Therapy in Boston, Massachusetts, April 5, and at the National Proton Conference run by the National Association on Proton Therapy in Boston, April 6-9.

RaySearch Laboratories AB announces the launch of RayStation®* 2024A, the latest version of the company’s comprehensive treatment planning system.

RaySearch Laboratories AB is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* - including the new ARTemis* OART solution under development - in combination with the Radixact® Treatment Delivery System from Accuray.

CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for January - September 2023 at a webcast to be held in English on Friday, November 17, 2023 at 10:00-10:30 a.m. CET.

The number of radiation therapy centers that have chosen RayStation for treatment planning now exceeds 1,000.

Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

RaySearch Laboratories AB is pleased to announce that the longterm collaboration/partnership with the innovative center EBG MedAustron GmbH in Wiener Neustadt in Austria will be further expanded through a new research agreement.